Scotiabank raised the firm’s price target on Vera Therapeutics (VERA) to $65 from $55 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment
- Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment
- H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data
- Vera Therapeutics Announces Positive Phase 3 Trial Results
- Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept